Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BRIEF-BioCryst receives more funding for developing treatment for hemorrhagic fever virus diseases

By: Reuters: Company News
* Funding represents an additional $5.5 million to BioCryst for development of BCX4430 as a treatment for hemorrhagic fever viruses
Related Stocks:
Biocryst Pharma Inc
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.